CD274 and neoplasm: The phase II, nonrandomized, 2-cohort (arm A, squamous and non-squamous histology; arm B, non-squamous histology), open-label KEYNOTE-799 study showed that pembrolizumab plus cCRT provided robust anti-tumor activity (ORR, 70.5%) with a manageable safety profile for patients with previously untreated, stage III, unresectable LA-NSCLC, regardless of tumor histologic type and PD-L1 expression [71].